Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients.

Yamada S, Takagi H, Tsuchiya H, Nakajima T, Ochiai H, Ichimura A, Iwata H, Toriyama T.

Yakugaku Zasshi. 2007 Sep;127(9):1491-6.

2.

Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.

Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.

Osteoporos Int. 2012 Mar;23(3):1083-90. doi: 10.1007/s00198-011-1800-1.

PMID:
21975559
3.

Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.

Ringe JD, Faber H, Fahramand P, Schacht E.

J Rheumatol Suppl. 2005 Sep;76:33-40.

PMID:
16142849
4.

A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).

Shiraki M, Fukunaga M, Kushida K, Kishimoto H, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H.

Osteoporos Int. 2003 May;14(3):225-34. Epub 2003 Apr 10.

PMID:
12730746
5.

Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study.

Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K.

J Bone Miner Metab. 2009;27(2):168-74. doi: 10.1007/s00774-008-0024-8. Epub 2009 Jan 28.

PMID:
19183836
6.

Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.

Devogelaer JP, Sambrook P, Reid DM, Goemaere S, Ish-Shalom S, Collette J, Su G, Bucci-Rechtweg C, Papanastasiou P, Reginster JY.

Rheumatology (Oxford). 2013 Jun;52(6):1058-69. doi: 10.1093/rheumatology/kes410. Epub 2013 Jan 30.

PMID:
23365149
7.

Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis.

Kitazaki S, Mitsuyama K, Masuda J, Harada K, Yamasaki H, Kuwaki K, Takedatsu H, Sugiyama G, Tsuruta O, Sata M.

Aliment Pharmacol Ther. 2009 Feb 15;29(4):424-30. doi: 10.1111/j.1365-2036.2008.03899.x. Epub 2008 Nov 25.

8.

Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis.

Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW.

Rheumatol Int. 2004 Mar;24(2):63-70. Epub 2003 Sep 25.

PMID:
14513268
9.

A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.

Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H; Risedronate Phase III Research Group..

Osteoporos Int. 2002 Dec;13(12):971-9.

PMID:
12459940
10.

Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome.

Takei T, Itabashi M, Tsukada M, Sugiura H, Moriyama T, Kojima C, Shiohira S, Shimizu A, Karasawa K, Amemiya N, Kawanishi K, Ogawa T, Uchida K, Tsuchiya K, Nitta K.

Intern Med. 2010;49(19):2065-70. Epub 2010 Oct 1.

11.
12.

Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol.

Takeda S, Kaneoka H, Saito T.

Mod Rheumatol. 2008;18(3):271-6. doi: 10.1007/s10165-008-0055-y. Epub 2008 Apr 22.

PMID:
18427724
14.

Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.

Sambrook PN, Roux C, Devogelaer JP, Saag K, Lau CS, Reginster JY, Bucci-Rechtweg C, Su G, Reid DM.

Bone. 2012 Jan;50(1):289-95. doi: 10.1016/j.bone.2011.10.024. Epub 2011 Oct 29. Erratum in: Bone. 2012 Mar;50(3):811.

PMID:
22061864
15.

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.

Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN; HORIZON investigators..

Lancet. 2009 Apr 11;373(9671):1253-63. doi: 10.1016/S0140-6736(09)60250-6.

PMID:
19362675
16.

Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.

Ringe JD, Farahmand P, Faber H, Dorst A.

Rheumatol Int. 2009 Jan;29(3):311-5. doi: 10.1007/s00296-008-0689-2. Epub 2008 Sep 2.

PMID:
18762944
17.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
18.

Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy.

Okada Y, Nawata M, Nakayamada S, Saito K, Tanaka Y.

J Rheumatol. 2008 Nov;35(11):2249-54.

PMID:
19031508
19.

Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.

Reginster JY, Lecart MP, Richy F.

J Rheumatol Suppl. 2005 Sep;76:21-5.

PMID:
16142847
20.

Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial.

Glüer CC, Marin F, Ringe JD, Hawkins F, Möricke R, Papaioannu N, Farahmand P, Minisola S, Martínez G, Nolla JM, Niedhart C, Guañabens N, Nuti R, Martín-Mola E, Thomasius F, Kapetanos G, Peña J, Graeff C, Petto H, Sanz B, Reisinger A, Zysset PK.

J Bone Miner Res. 2013 Jun;28(6):1355-68. doi: 10.1002/jbmr.1870.

Supplemental Content

Support Center